How to harness the power of AI and real-world data for clinical research

Research suggests that it costs an average of $2.6 billion and takes at least ten years to develop a new medicine, and the probability that a drug entering clinical testing will eventually be approved is estimated to be less than 12%. 

Optimising the clinical trials phase of drug development is key to bringing new, potentially life-saving therapies to market sooner. 

By combining the power of artificial intelligence with real-world patient data, we are now in a position to deliver intelligent insights that can transform clinical design, completing more trials across multiple therapeutic areas faster and at a reduced cost.

Randomised Controlled Trials (RCTs) have long been considered the gold standard for the evaluation of new therapies. However, these trials can be long, expensive and resource intensive. 

 By combining the power of artificial intelligence with real-world patient data, we are now in a position to deliver intelligent insights that can transform clinical design, completing more trials across multiple therapeutic areas faster, and at a reduced cost.